TNFSF10 and cancer: Based on the observation that adoptive T-cell therapy often fails to induce meaningful anticancer responses in cancer patients, the Bremer laboratory developed fusion proteins of TRAIL where the extracellular portion of TRAIL was fused with either an antibody fragment recognizing the T cell surface molecule CD3 or with K12, the ligand of another T cell marker, CD7 (154).